BioVersys 2025 Results: Clinical Milestones and Funding Resilience in AMR
BioVersys AG reported its full-year 2025 financial results, highlighting significant clinical progress for its lead antimicrobial candidates and a stable cash position. The Swiss biotech successfully advanced its AlpE program into Phase 2b trials, reinforcing its leadership in the fight against multi-drug resistant infections.